Innovative Computing Solutions and MedTech

by | Jul 21, 2021 | 3D Printing, AI, Analytics, Medical Devices, MedTech

The rapid expansion of computing is attributed to the consistent improvement in capabilities, speed, and performance from the collective efforts of electrical and computer science engineers. Nearly every two years, these developers tend to double the number of components in an integrated computer chip, first observed by Gordon Moore in 19751. This has since been the basis of Moore’s law, which centers around the number of transistors a microchip can contain. However, there are obvious physical limitations to this law so there have been recently developed alternative approaches that have a promising outlook for extending, or at the very least complementing Moore’s law1.

Since the inception of the 3D printer, the possible applications have been far and wide with buzzing optimism. One application pertaining to Moore’s law is 3D printing complex functional circuits and electrical driven devices using Additively Manufactured Electronic (AME) Technology and Systems. This form of 3D printing is labeled as 3D heterogeneous integration. The underlying feature of this method allows engineers to define every voxel (3D pixel) as either a conductor or isolator. Potential uses of this technology can be foreseen in approaches such as molecular transistors, and quantum, biological, protein, and DNA computers. The versatility is unique because of the various disciplines 3D heterogeneous integration can work into a single product, such as electrical, optical, thermal, magnetic, or mechanical properties1.

Quality and regulatory play a pivotal role in introducing state-of-the-art technology into the medical industry such as the 3D heterogeneous integration. While advantages are inherently present, there must be adequately developed processes and procedures in place to mitigate liabilities and overall risk. These processes and procedures are not easy to establish and implement, but QA/RA experts will provide a thorough methodology that will walk through every facet of newly introduced technology. At EMMA International, the team uses a multitude of current published standards to help those with all QA/RA needs for a diverse range of medical technology, pharmaceuticals, and biologics. With the rapid innovation of computing year after year affecting practically every industry, especially healthcare, quality and regulatory must be enforced to avoid design assumptions with catastrophic capabilities.

EMMA International is here to provide full-circle solutions for all sectors of the MedTech industry. Give us a call at 248-987-4497 or email us at info@emmainternational.com to learn more about how EMMA International can help with quality and regulatory compliance today!

[1] Nanodimension (2021) How 3D integrated components can take us beyond Moore’s Law, Retrieved on 20 July 2021 from: https://www.nanodi.com/hubfs/2021_Marketing_Assets/Moore_Law_Nano_Dimension.pdf?li_fat_id=c5de632d-9d8f-4ec1-93a6-b5b2dadef17f

Zach Nies

Zach Nies

Quality Engineer (Co-Op) - Mr. Nies has experience in combination products, pharmaceuticals, and FDA compliance for many life science industries. He has experience with many different elements of quality and regulatory compliance. Mr. Nies is completing a Bachelor of Engineer degree in Biomedical Engineering from Wayne State University.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This